keyboard_arrow_up

Alzheimer Disease Therapeutics Market 2019 Forecasts

RnRMarketResearch.com adds report “Alzheimer’s Disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation” to its store.

GBI Research has released its pharmaceuticals report: “Alzheimer’s Disease Therapeutics Market to 2019 – Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation”. The Alzheimer’s Disease (AD) market is characterized by a lack of products with strong disease-modifying properties and a number of high-profile product failures in late stages of development over recent years. In addition, recent or impending patent expiries for all of the four currently marketed products and a late-stage pipeline with limited-to-moderate prospects are expected to impede growth over the next few years. In the medium-term future, the market is expected to be characterized by substantial generic competition and overall decline. However, the current development pipeline shows signs of meaningful innovation, although the vast majority of these products are currently in the early stages of development. Despite one of the highest drug attrition rates across the industry, a number of innovative and potentially disease-modifying therapeutics are likely to enter the market and translate recent insights into the etiology of AD combined with an earlier therapeutic intervention into better products, which will begin to transform the AD market towards the end of the decade.

Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=127325 .

Scope

  • A brief introduction to AD etiology, pathogenesis, diagnosis, and treatment regimes
  • Profiling of the marketed products in the AD market, including analysis of their safety, efficacy, treatment patterns, and strengths and weaknesses
  • Comprehensive review of the pipeline for AD therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule type, and molecular target.
  • Additional in-depth analysis of pipeline drug clinical trials, analyzed by phase, molecule type, trial size, trial duration and program failure rate, for each molecule type and mechanism of action
  • Multi-scenario forecast data for the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers of and barriers to market growth
  • Analysis of the licensing and co-development deals landscape

Complete report is available @ http://www.rnrmarketresearch.com/alzheimers-disease-therapeutics-market-to-2019-early-stage-innovation-points-to-disease-modifying-therapies-and-market-transformation-market-report.html .

Reasons to Buy

  • Understand the different levels of AD therapies, from early-stage or mild AD to severe AD
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe trends in terms of clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for AD therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the AD therapeutics market

Inquire for discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=127325 .

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 8
2.1 Symptoms 8
2.2 Etiology 9
2.3 Pathophysiology 10
2.3.1 Amyloidosis 10
2.3.2 Tau Hyperphosphorylation 10
2.4 Comorbidities/Complications 11
2.5 Diagnosis 11
2.5.1 Physical Examination 12
2.5.2 Mini Mental State Exam 12

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=127325 .

Browse Alzheimer Drugs Industry Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/alzheimer-drugs .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter : https://twitter.com/#!/RnRMR

Facebook : http://www.facebook.com/pages/RnR-Market-Research/413488545356345

Google Plus : https://plus.google.com/u/0/104156468549256253075/